Canadian health authorities have officially authorised pharmaceutical giant Moderna to launch clinical trials for an experimental Ebola vaccine.
This Phase 1 trial will evaluate the candidate’s safety, determine precise dosage ranges, and monitor potential side effects.
Scientists are targeting the deadly Bundibugyo strain, an unyielding variant currently driving a severe outbreak across Central Africa.
More than 1,700 lives have already been lost in the Democratic Republic of Congo since May.
The promising candidate utilizes the groundbreaking mRNA technology that previously proved crucial during the global COVID-19 pandemic.
Healthy trial volunteers will receive initial doses to measure their immune system’s specific antibody responses against the virus.
To fortify national health security, Canada has secured an agreement to manufacture the experimental doses directly on domestic soil.
There are currently no approved medical treatments or preventive vaccines specifically designed to stop the lethal Bundibugyo variant.
Global health organizations remain on high alert as multiple alternative candidates race through preliminary international development.
Researchers hope these vital human trials offer a crucial breakthrough in halting the relentless, hemorrhagic fever-inducing virus.
